5FNC1†Present address: Division of Pharmaceutical Sciences, Strathclyde Institute of Pharmacy & Biomedical Sciences (SIPBS), John Arbuthnott Building, University of Strathclyde, Glasgow, UK.
Equine sarcoids are fibroblastic skin tumours affecting equids worldwide. While the pathogenesis is not entirely understood, infection with bovine papillomavirus (BPV) type 1 (and less commonly type 2) has been implicated as a major factor in the disease process. Sarcoids very seldom regress and in fact often recrudesce following therapy. Nothing is known about the immune response of the equine host to BPV. Given that the viral genes are expressed in sarcoids, it is reasonable to assume that vaccination of animals against the expressed viral proteins would lead to the induction of an immune response against the antigens and possible tumour rejection. To this end we vaccinated sarcoid-bearing donkeys in a placebo-controlled trial using chimeric virus-like particles (CVLPs) comprising BPV-1 L1 and E7 proteins. The results show a tendency towards enhanced tumour regression and reduced progression in the vaccinated group compared to control animals. Although promising, further studies are required with larger animal groups to definitely conclude that vaccination with CVLPs is a potential therapy for the induction of sarcoid regression.
AshrafiG. H.,
TsirimonakiE.,
MarchettiB.,
O'BrienP. M.,
SibbetG. J.,
AndrewL.,
CampoM. S.2002; Down-regulation of MHC class I by bovine papillomavirus E5 oncoproteins. Oncogene 21:248–259[CrossRef]
CampoM. S.2006; Bovine papillomavirus: old system, new lessons? In Papillomavirus Research: from Natural History to Vaccines and Beyond . pp 373–387Edited byCampoM. S.
Norfolk, UK: Caister Academic Press;
CampoM. S.,
GrindlayG. J.,
O'NeilB. W.,
ChandrachudL. M.,
McGarvieG. M.,
JarrettW. F.1993; Prophylactic and therapeutic vaccination against a mucosal papillomavirus. J Gen Virol 74:945–953[CrossRef]
CampoM. S.,
O'NeilB. W.,
GrindlayG. J.,
CurtisF.,
KnowlesG.,
ChandrachudL.1997; A peptide encoding a B-cell epitope from the N-terminus of the capsid protein L2 of bovine papillomavirus-4 prevents disease. Virology 234:261–266[CrossRef]
CarrE. A.,
ThéonA. P.,
MadewellB. R.,
HitchcockM. E.,
SchlegelR.,
SchillerJ. T.2001; Expression of a transforming gene (E5) of bovine papillomavirus in sarcoids obtained from horses. Am J Vet Res 62:1212–1217[CrossRef]
ChambersG.,
EllsmoreV. A.,
O'BrienP. M.,
ReidS. W. J.,
LoveS.,
CampoM. S.,
NasirL.2003; Sequence variants of bovine papillomavirus E5 detected in equine sarcoids. Virus Res 96:141–145[CrossRef]
ChandrachudL. M.,
O'NeilB. W.,
JarrettW. F.,
GrindlayG. J.,
McGarvieG. M.,
CampoM. S.1994; Humoral immune response to the E7 protein of bovine papillomavirus type 4 and identification of B-cell epitopes. Virology 200:98–104[CrossRef]
ChandrachudL. M.,
GrindlayG. J.,
McGarvieG. M.,
O'NeilB. W.,
WagnerE. R.,
JarrettW. F.,
CampoM. S.1995; Vaccination of cattle with the N-terminus of L2 is necessary and sufficient for preventing infection by bovine papillomavirus-4. Virology 211:204–208[CrossRef]
ColemanN.,
BirleyH. D.,
RentonA. M.,
HannaN. F.,
RyaitB. K.,
ByrneM.,
Taylor-RobinsonD.,
StanleyM. A.1994; Immunological events in regressing genital warts. Am J Clin Pathol 102:768–774
CotzerJ. A. W.,
GuthrieA. J.2004; African horse sickness. In Infectious Diseases of Livestock pp 1231–1246Edited byCoetzerJ. A. W.,
TustinR. C.
Oxford: Oxford University Press;
GovanV. A.2005; Strategies for human papillomavirus therapeutic vaccines and other therapies based on the E6 and E7 oncogenes. Ann N Y Acad Sci 1056:328–343[CrossRef]
HowellP. G.,
GuthrieA. J.,
CoetzerJ. A. W.2004; Equine encephalosis. In Infectious Diseases of Livestock pp 1247–1251Edited byCoetzerJ. A. W.,
TustinR. C.
Oxford: Oxford University Press;
JacksonC.1936The incidence and pathology of tumours of domesticated animals in South Africa pp 378–385 Pretoria, South Africa: Union of South Africa, Department of Agriculture;
JarrettW. F.,
SmithK. T.,
O'NeilB. W.,
GaukrogerJ. M.,
ChandrachudL. M.,
GrindlayG. J.,
McGarvieG. M.,
CampoM. S.1991; Studies on vaccination against papillomaviruses: prophylactic and therapeutic vaccination with recombinant structural proteins. Virology 184:33–42[CrossRef]
KirnbauerR.,
ChandrachudL. M.,
O'NeilB. W.,
WagnerE. R.,
GrindlayG. J.,
ArmstrongA.,
McGarvieG. M.,
SchillerJ. T.,
LowyD. R.,
CampoM. S.1996; Virus-like particles of bovine papillomavirus type 4 in prophylactic and therapeutic immunization. Virology 219:37–44[CrossRef]
LancasterW. D.,
TheillenG. H.,
OlsonC.1979; Hybridisation of bovine papillomavirus type 1 and type 2 DNA to DNA from virus-induced hamster tumours and naturally occurring equine tumours. Intervirology 11:227–233[CrossRef]
MarchettiB.,
AshrafiG. H.,
TsirimonakiE.,
O'BrienP. M.,
CampoM. S.2002; The papillomavirus oncoprotein E5 retains the major histocompatibility class I in the Golgi apparatus and prevents its transport to the cell surface. Oncogene 21:7808–7816[CrossRef]
MarchettiB.,
AshrafiG. H.,
DornanE. S.,
AraibiE. H.,
EllisS. A.,
CampoM. S.2006; The E5 protein of BPV-4 interacts with the heavy chain of MHC class I and irreversibly retains the MHC complex in the Golgi apparatus. Oncogene 27:2254–2263
Mattil-FritzS.,
ScharnerD.,
PiukoK.,
ThönesN.,
GissmannL.,
MüllerH.,
MüllerM.2008; Immunotherapy of equine sarcoid: dose escalation trial for the use of chimeric papillomavirus-like particles. J Gen Virol 89:138–147[CrossRef]
MejiaA. F.,
CulpT. D.,
CladelN. M.,
BaloghK. K.,
BudgeonL. R.,
BuckC. B.,
ChristensenN. D.2006; Preclinical model to test human papillomavirus virus (HPV) capsid vaccines in vivo using infectious HPV/cottontail rabbit papillomavirus chimeric papillomavirus particles. J Virol 80:12393–12397[CrossRef]
NasirL.,
ReidS. W. J.2006; Bovine papillomaviruses and equine sarcoids. In Papillomavirus Research: from Natural History to Vaccines and Beyond . pp 389–397Edited byCampoM. S.
Norfolk, UK: Caister Academic Press;
NewtonJ. R.,
MumfordJ. A.2004; Equine influenza. In Infectious Diseases of Livestock pp 766–774Edited byCoetzerJ. A. W.,
TustinR. C.
Oxford: Oxford University Press;
OkabayashiM.,
AngellM. G.,
ChristensenN. D.,
KreiderJ. W.1991; Morphometric analysis and identification of infiltrating leucocytes in regressing and progressing Shope rabbit papillomas. Int J Cancer 49:919–923[CrossRef]
PascoeR. R.,
SummersP. M.1981; Clinical survey of tumours and tumour-like lesions in horses in south east Queensland. Equine Vet J 13:235–239[CrossRef]
ReidS. W.,
GettinbyG.,
FowlerJ. N.,
IkinP.1994; Epidemiological observations on sarcoids in a population of donkeys ( Equus asinus ). Vet Rec 134:207–211[CrossRef]
RodenR. B. S.,
ViscidiR. P.2006; Papillomavirus-like particles and their applications in molecular virology, human serology and vaccines. In Papillomavirus Research: from Natural History to Vaccine and Beyond pp 279–310Edited byCampo.
Norfolk, UK: Caister Academic Press;
SaslowD.,
CastleP. E.,
CoxJ. T.,
DaveyD. D.,
EinsteinM. H.,
FerrisD. G.,
GoldieS. J.,
HarperD. M.,
KinneyW.other authors2007; American Cancer Society guideline for human papillomavirus (HPV) vaccine use to prevent cervical cancer and its precursors. CA Cancer J Clin 57:7–28[CrossRef]
YuanZ.,
GallagherA.,
GaultE. A.,
CampoM. S.,
NasirL.2006; Bovine papillomavirus infection in equine sarcoids and in bovine bladder cancers. Vet J 174:599–604
YuanZ.,
PhilbeyA. W.,
GaultE. A.,
CampoM. S.,
NasirL.2007; Detection of bovine papillomavirus type 1 genomes and viral gene expression in equine inflammatory skin conditions. Virus Res 124:245–249[CrossRef]